Abstract
Infantile fibrosarcoma (IFS) is a rare pediatric cancer that typically presents early in life. Surgical resection is commonly curative; however, resection is sometimes not possible requiring additional multimodal treatment. IFS commonly harbors a fusion in one of the neurotrophic receptor tyrosine kinase (NTRK) genes. Larotrectinib, a highly selective inhibitor of tropomyosin receptor kinase (TRK), has been shown to be well tolerated and effective in children as young as 1-month old. We report a case of IFS in a newborn treated with larotrectinib. The patient experienced a rapid clinical and radiographic response demonstrating the potential to treat newborns with larotrectinib.
Keywords:
NTRK; infantile fibrosarcoma; larotrectinib; pediatric.
© 2020 Wiley Periodicals, Inc.
MeSH terms
-
Fibrosarcoma / drug therapy*
-
Humans
-
Infant, Newborn
-
Male
-
Membrane Glycoproteins / antagonists & inhibitors
-
Membrane Glycoproteins / genetics
-
Oncogene Proteins, Fusion / genetics
-
Protein Kinase Inhibitors / therapeutic use*
-
Protein Kinases / drug effects
-
Pyrazoles / therapeutic use*
-
Pyrimidines / therapeutic use*
-
Receptor, trkA / antagonists & inhibitors
-
Receptor, trkA / genetics
-
Receptor, trkB / antagonists & inhibitors
-
Receptor, trkB / genetics
-
Receptor, trkC / antagonists & inhibitors
-
Receptor, trkC / genetics
Substances
-
Membrane Glycoproteins
-
NTRK1 protein, human
-
NTRK3 protein, human
-
Oncogene Proteins, Fusion
-
Protein Kinase Inhibitors
-
Pyrazoles
-
Pyrimidines
-
Protein Kinases
-
Receptor, trkA
-
Receptor, trkB
-
Receptor, trkC
-
tropomyosin-related kinase-B, human
-
tropomyosin kinase
-
larotrectinib